Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agomir-511-5p
- Development stage
- Preclinical
- Lead developer
- AptamiR Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Agomir-511-5p is a synthetic, chemically modified double-stranded microRNA (miRNA) mimic designed to replicate the biological activity of endogenous miR-511-5p. It is primarily utilized in preclinical research to investigate the tumor-suppressive roles of miR-511-5p. In lung squamous cell carcinoma (SQC), miR-511-5p has been identified as a regulator of angiogenesis by directly targeting the 3' untranslated region (UTR) of Vascular Endothelial Growth Factor A (VEGFA) mRNA, leading to its degradation or translational inhibition. The long noncoding RNA LINC00173.v1 can sequester miR-511-5p, thereby upregulating VEGFA and promoting tumor progression. Agomir-511-5p serves to counteract this effect by restoring miR-511-5p levels, making it a potential candidate for anti-angiogenic RNA therapy.
- Other names
- miR-511-5p agomirmiR511-5p agomirmiR 511-5p agomirmicroRNA-511-5p agomirmicroRNA511-5p agomirmicroRNA 511-5p agomirmiR-511-5p mimicmiR511-5p mimicmiR 511-5p mimic
02
Targets
Beyond the preview
Go deeper on agomir-511-5p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agomir-511-5p.